Description: Intellia advances in vivo pipeline with lonvo-z through its pivotal HAELO study, eyeing mid-2026 data and a potential 2026 filing to propel growth.

Description: Regeneron Pharmaceuticals has underperformed the S&P 500 over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Description: Regeneron Pharmaceuticals and Sanofi recently announced that the European Commission approved Dupixent as a first-line treatment for moderate-to-severe chronic spontaneous urticaria (CSU) in patients aged 12 and older who do not respond to antihistamines and are naive to anti-IgE therapy, based on positive Phase 3 clinical trial results. This marks the first innovation for CSU patients in Europe in over a decade and potentially opens access for approximately 270,000 eligible...

Description: Sanofi (NASDAQ:SNY) is one of the best low volatility large cap stocks to invest in. Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Sanofi (NASDAQ:SNY) on November 25, setting a €110 price target. The same day, Sanofi (NASDAQ:SNY) announced the approval of Dupixent (dupilumab) by the European Commission for the treatment of “moderate-to-severe chronic […]

Description: Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: Market growth is propelled by improved diagnosis, genetic screening, and emerging therapies like statins, PCSK9 inhibitors, and gene therapies. Challenges include underdiagnosis and delayed treatment. Key players like Regeneron and Amgen are pioneering innovative solutions, enhancing the market landscape with precision medicine and genetic advancements.Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Familial Hypercholesterolemia Market - A Global and Regional Analysis: Focus on Country and Region

Description: Beam's broad early-stage pipeline and recent study progress take center stage as investors weigh its potential against rival NTLA's prospects.

Description: The approval marks the first for a targeted treatment in chronic spontaneous urticaria in Europe in over a decade.

Description: The S&P 500 Health Care Index is up 10% through Tuesday, outperforming the other 10 sectors in the benchmark for US stocks. Eli Lilly & Co. has surged 29% to become the first health company with a $1 trillion valuation. Regeneron Pharmaceuticals Inc., Merck & Co. and Biogen Inc. are all up at least 18% since the end of October.

Description: Regeneron Pharmaceuticals (REGN) shares have shown steady gains over the past month, supported by the company’s consistent revenue and net income growth. Investors are keeping an eye on how Regeneron continues to execute on its existing strengths. See our latest analysis for Regeneron Pharmaceuticals. Regeneron’s impressive 36% one-month share price return has given it real momentum, especially when you consider its steady gains earlier in the year. Over a five-year period, its total...

Description: Sanofi/Regeneron's Dupixent wins EU nod for chronic spontaneous urticaria, marking its seventh approved indication across inflammatory diseases in the EU.

Description: Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatment Dupixent, which inhibits IL-4 and IL-13, two key and central drivers of type 2 inflammation, is now approved for patients across seven chronic, inflammatory diseases in the EU TARRYTOWN, N.Y. and PARIS,

Description: Bayer issued a "surprisingly positive" report for its blood thinner over the weekend, prodding Bristol Myers Squibb stock higher on Monday.

Description: Markets are dipping lower this month, but positive news from the FDA has this biotech stock ripping higher.

Description: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the stocks Jim Cramer answered questions about. Answering a caller’s query about the stock, Cramer stated: “I should have been recommending Regeneron. That Len Schleifer pulled the rabbit out of a hat. It’s coming right back right now. By the way, I’ll give you a twofer, so is […]

Description: Curious if Regeneron Pharmaceuticals is actually worth its current price tag? You are not alone; investors across the board are wondering whether now is the right time to add it to their portfolios. Shares have jumped 29.3% over the past month, including a 9.0% rise in just the last week. This has definitely caught the market’s attention and may signal shifting expectations on growth or risk. Recent headlines have highlighted promising clinical trial updates and new drug approvals. Both of...

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to

Description: Intellia sinks 67% in a month after a clinical hold on nex-z and mixed third-quarter results, raising questions about its pipeline outlook and near-term direction.

Description: Healthcare stocks have outperformed the broader market by nearly 10 percentage points this month as AI bubble concerns have weighed on tech stocks.

Description: Regeneron Pharmaceuticals has underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

Description: The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing growth, increasing competition, or unsustainable valuations.

Description: ↗️ Walmart (WMT): The biggest U.S. retailer and private-sector employer posted solid quarterly results and raised its outlook. Shares closed up nearly 6.5%. ↘️Nvidia (NVDA): The chip maker reported record sales and issued strong guidance, helping ease angst about an artificial-intelligence bubble.

Description: Regeneron gains EC approval to expand Libtayo's use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion.

Description: Eylea HD’s new RVO indication and a monthly dosing option will notch up the rivalry with Roche’s Vabysmo.

Description: Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.

Description: First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing option in all approved indications provides greater dosing flexibility for more personalized patient care TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD® (aflibercept) Injection 8 mg for the treatment of patients with macu

Description: Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free survival in CSCC in the adjuvant setting, reducing the risk of recurrence or death by 68% (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p<0.0001) Libtayo is the current standard of care in advanced CSCC in Europe, and this approval has the potential to change the treatment paradigm for patients in an earlier setting TARRYTOWN, N.Y., Nov. 19, 2025 (G

Description: The Dow Jones index fell on the stock market today. Lithium stocks rose on bullish commentary. Alphabet jumped on a Warren Buffett move but Peter Thiel dumped a key AI stock.

Description: Shares of Bristol Myers Squibb slumped Friday after the company scrapped a study testing a treatment for acute coronary syndrome.

Description: Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

Description: Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this setting Additional oral presentation spotlights data for odronextamab in combination with chemotherapy, without rituximab, as a frontline treatment for diffuse large B-cell lymphoma Other presentations span a broad range of hematologic conditions, including paroxysmal nocturnal hemoglobinuria and severe

Description: These top growth stocks have plenty of room left to run.

Description: Regeneron Pharmaceuticals (REGN) shares have been in focus recently, attracting investor interest thanks to their steady revenue and net income growth over the past year. The stock has gained 16% in the past month alone. See our latest analysis for Regeneron Pharmaceuticals. After a challenging stretch, Regeneron’s recent 1-month share price return of nearly 16% suggests that momentum may finally be turning upward, despite the fact that the 1-year total shareholder return is still down almost...

Description: The daily pill reduced LDL cholesterol by 56% in just six months, among patients whose LDL defy treatment with everyday statin drugs.

Description: European stock markets surged in Monday trading on investor optimism that the end of the US governme

Description: Patients treated with Dupixent were 92% less likely to need corticosteroids or surgery.

Description: Looking back on immuno-oncology stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Regeneron (NASDAQ:REGN) and its peers.

Description: REYKJAVIK, Iceland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of expedited infringement proceedings before the UK High Court by Regeneron Pharmaceuticals Inc. (“Regeneron”) and Bayer AG (“Bayer”) against Alvotech and its contract manufacturing organization (CMO) in the United Kingdom. The court rejected Regeneron’s and Bayer’s injun

Description: In recent days, Regeneron Pharmaceuticals announced detailed positive Phase 2 trial results for two novel factor XI antibodies aimed at preventing blood clotting in total knee replacement surgery patients. This progress highlights Regeneron's continued expansion into new therapeutic areas, potentially strengthening the company's position in advancing specialty biologics for unmet clinical needs. We'll explore how these encouraging trial outcomes for the investigational factor XI antibodies...

Description: Merck said Saturday its new pill — a potential rival to Regeneron and Amgen — lowered stubbornly high cholesterol by almost 60%.

Description: Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement Trial results consistent with prospective design of these antibodies to have distinct profiles – one to provide stronger anticoagulation and the other to have a lower risk of bleeding – potentially allowing physicians to tailor anticoagulant therapy for patients with different risk profiles Phase 3 trials in patients

Description: Despite a narrower Q3 loss, NTLA stock plunges after pulling nex-z milestone guidance amid FDA scrutiny in amyloidosis patients.

Description: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion, and nasal polyps in patients aged 6 years and older compared to placeboDupixent sBLA accepted for priority review by the US FDA with a target acti

Description: Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years and older compared to placebo Dupixent sBLA accepted for priority review by the U.S. FDA with a target action date of February 28, 2026 If approved, Dupixent would be the first and only medicine indicated specifically for AFRS, which would be its ninth FDA-approved indication AFRS is a chronic type

Description: Awaiting FDA clinical hold letter on MAGNITUDE and MAGNITUDE-2 clinical trials of nex-zPresenting longer-term Phase 1 clinical data of nex-z for ATTR-CM on November 10 at AHA 2025; previously published longer-term Phase 1 clinical data for nex-z for ATTRv-PN in New England Journal of MedicineCompleted enrollment in Phase 3 HAELO clinical trial of lonvo-z for HAE; topline data expected by mid-2026 with potential U.S. commercial launch in 1H27Presenting longer-term Phase 1/2 clinical data of lonvo

Description: NEW YORK, November 06, 2025--Life Sciences, TechBio, and Investment Leaders at Demy-Colton’s BioFuture™ 2025 Suggest Health and Biotech Sectors Show Signs of New Life

Description: Wondering if Regeneron Pharmaceuticals is a hidden gem or just fairly priced? You are not alone; investors everywhere are asking whether now is the right moment to jump in or sit on the sidelines. The stock's journey lately has been anything but dull. It saw a 4.7% rise over the past month after sliding 4.0% in the last week, while the shares remain down 24.0% over the past year. Recent headlines have highlighted Regeneron's expanding drug pipeline and ongoing innovations in treating rare...

Description: RARE's Q3 loss widens and revenues miss estimates, despite year-over-year sales growth of key rare disease drugs.

Description: A new regulatory filing shows that billionaire investor Michael Burry's hedge fund Scion Asset Management purchased five million put options on Palantir Technologies, Inc. (NASDAQ:PLTR) and one million put options on NVIDIA Corp. (NASDAQ:NVDA), among ...

Description: Regeneron’s third quarter results were well received by the market, reflecting strong execution in its commercial portfolio and key products. Management attributed the positive momentum to double-digit sales growth for Dupixent, Libtayo, and EYLEA HD, despite flat overall sales. CEO Leonard Schleifer highlighted that Dupixent’s broadening indications and robust uptake across geographies remained a primary growth driver, while EYLEA HD benefited from increased physician demand, partially offset b

Description: TARRYTOWN, N.Y., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Jefferies London Healthcare Conference at 3:30 p.m. GMT (10:30 a.m. ET) on Monday, November 17, 20257th Annual Wolfe Research Healthcare Conference at 9:20 a.m. ET on Monday, November 17, 20258th Annual Evercore Healthcare Conference at 1:20 p.m. ET on Tuesday, December 2, 2025Citi 2025 Global Healthcare Conference at 10:30 a.m. ET on Wednesday, Dece

Description: It would be best to get in before the rest of the market pounces on these opportunities.

Description: Maybe Cathie Wood and Wall Street are being too optimistic.

Description: OPKO Health recently reported third-quarter earnings with revenue of US$151.67 million and net income of US$21.63 million, surpassing analyst expectations, and announced a collaboration with Regeneron Pharmaceuticals potentially valued at over US$1 billion. The company also finalized the US$225 million sale of its BioReference Health oncology assets to Labcorp and received FDA approval for broader use of its 4Kscore® Test, marking significant changes in its business focus and regulatory...

Description: While gefurulimab offered significant improvements to MG-ADL scores, it was bested by a variety of pipeline and marketed gMG drugs.

Description: Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions First and only therapy to specifically target the IL-4 and IL-13 signaling pathway, a key driver of type 2 inflammation that contributes to multiple conditions TARRYTOWN, N.Y., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Dupixent® (dupilumab) has been recognized as the “Best Biotechnology Produ

Description: JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the execution of an Amendment to its strategic collaboration agreement with Regeneron Pharmaceuticals, Inc. ("Regeneron"), a leading global biotechnology company. This amendment not only signifies a major upgrade in long-term partnership between the two companies, but also marks the beginning of a new phase of collabora

Description: Opko Health Inc. (NASDAQ:OPK) is one of the best stocks under $5 with highest upside potential. ModeX Therapeutics Inc., an Opko Health Inc. (NASDAQ:OPK) company, announced on October 29 a license and collaboration agreement with Regeneron Pharmaceuticals Inc. for the development and discovery of multispecific antibodies for a number of therapeutic indications of mutual interest. […]

Description: Regeneron Pharmaceuticals (REGN) is forecasting annual earnings growth of 7.41%, with revenue also projected to rise by 7% per year, both lagging the broader US market's expected pace. The company’s net profit margin has narrowed to 32.1% from last year’s 33.6%. Over the past five years, earnings have declined by 4.6% per year and the company has reported negative year-over-year earnings growth. See our full analysis for Regeneron Pharmaceuticals. Next, we will see how these results fit with...

Description: Regeneron Pharmaceuticals recently saw its Fair Value price target increased from $722.20 to $735.72. This change comes on the heels of new earnings results and momentum within its drug pipeline. The revision reflects updated analyst models that weigh the strength of products like Eylea and Dupixent against evolving challenges in the regulatory and operational landscape. Stay tuned to discover how investors can monitor these ongoing shifts and remain informed as Regeneron's story...

Description: Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from the third quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX’s MSTAR technology platform with Re

Description: The 7% rally over the past month has been outdone only by technology stocks. The last two months alone have seen Metsera Avidity Biosciences Merus, 89bio and Akera Therapeutics all bought out. The stock, which many considered dead money at best since last summer, is suddenly finding favor with investors.

Description: Regeneron is planning to re-apply to the FDA with a new pre-filled syringe manufacturing filler in January 2026.

Description: Potential assets would target multiple biological pathways in a single molecule Total value of the partnership potentially exceeds $1 billion if multiple assets advance WESTON, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that it has entered into a license and collaboration agreement with Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) to discover and develop multispecific antibodies for several therapeutic indications of m

Description: The Morning Bull - US Market Morning Update Wednesday, Oct, 29 2025 US stock futures are narrowly mixed this morning as investors brace for a widely anticipated interest rate cut from the Federal Reserve. Attention is turning to what Chair Jerome Powell signals about the path ahead. Uncertainty around delayed economic data and stubbornly steady Treasury yields is keeping the mood cautious, prompting many investors to weigh how much easier borrowing costs could boost sentiment in the face of...

Description: Biotech company Regeneron (NASDAQ:REGN) reported Q3 CY2025 results exceeding the market’s revenue expectations, but sales were flat year on year at $3.75 billion. Its non-GAAP profit of $11.83 per share was 22.7% above analysts’ consensus estimates.

Description: Market data as of 4pm ET October 28, 2025 The market closed with yet another record win, once again credited to the increasing investments from companies well-versed in artificial intelligence. The S&P 500 closed 0.2% higher, maintaining its third consecutive day of record gains.The ...

Description: Regeneron stock advanced early Tuesday on better-than-expected third-quarter earnings despite a big tax hit.

Description: Intellia Therapeutics recently announced it has paused patient dosing and screening in its Phase 3 MAGNITUDE and MAGNITUDE-2 trials of nex-z for transthyretin amyloidosis following a serious liver-related adverse event in a patient dosed in late September 2025. The therapy, developed in collaboration with Regeneron and holding Orphan Drug and RMAT designations, is now under further safety evaluation as the company consults with regulatory authorities and medical experts. We'll examine how...

Description: US equity indexes rose on Tuesday, with the mainstream benchmark gauges breaking records ahead of th

Description: US equity indexes closed higher on Tuesday, hitting record highs during the day ahead of the Fed's e

Description: Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand.

Description: US equity indexes rose after midday on Tuesday, breaking records amid gains from quarterly earnings

Description: Health care stocks declined Tuesday afternoon, with the NYSE Health Care Index shedding 0.5% and the

Description: Shares of biotech company Regeneron (NASDAQ:REGN) jumped 8.7% in the morning session after it reported third-quarter financial results that surpassed analyst expectations for both revenue and profit.

Description: Yahoo Finance anchor Julie Hyman tracks Tuesday's top moving stocks and biggest market stories in this Market Minute. Nvidia (NVDA) is investing $1 billion in Nokia (NOK) and providing chips to the company for its 5G software. Westinghouse Electric, owned by Cameco (CCJ) and Brookfield (BAM), is partnering with the Trump administration to build nuclear reactors. Regeneron (REGN) stock is rising after the company's third quarter earnings results topped Wall Street's estimates. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Description: Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Description: Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q3 CY2025, but sales were flat year on year at $3.75 billion. Its non-GAAP profit of $11.83 per share was 22.7% above analysts’ consensus estimates.

Description: Regeneron (REGN) delivered earnings and revenue surprises of +25.32% and +4.38%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Investing.com - Regeneron has posted third-quarter revenue and profit which both topped Wall Street expectations, thanks to soaring demand for its anti-inflammatory drug.

Description: TARRYTOWN, N.Y. (AP) — Regeneron Pharmaceuticals Inc. REGN) on Tuesday reported third-quarter net income of $1.46 billion. On a per-share basis, the Tarrytown, New York-based company said it had net income of $13.62.

Description: Third quarter 2025 revenues increased 1% to $3.75 billion versus third quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 27% to $4.86 billion EYLEA HD® U.S. net sales increased 10% to $431 million; total EYLEA HD and EYLEA® U.S. net sales decreased 28% to $1.11 billion GAAP EPS of $13.62 and non-GAAP EPS(a) of $11.83; third quarter 2025 includes unfavorable $0.68 impact from acquired IPR&D chargeFDA approved Libtayo® as the first and only immunotherapy for high-risk adjuvant

Description: Conference call today at 8:30 a.m. ETCAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company has temporarily paused patient dosing and screening for its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials of nex-z for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN), r

Description: DALLAS, October 27, 2025--OncoNano Medicine, Inc. ("OncoNano") announced encouraging first-in-human results from Part 1 of its Phase 1 ON-5001 trial evaluating ONM-501, a dual-acting STING agonist, as monotherapy and in combination with Libtayo® (cemiplimab), Regeneron’s PD-1 inhibitor, in patients with advanced solid tumors and lymphomas. The findings were shared during a poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, M

Description: Regeneron Pharmaceuticals (REGN) just moved a step closer to expanding its cancer therapy portfolio in Europe after the European Medicines Agency’s committee issued a positive opinion for Libtayo as an adjuvant treatment for certain skin cancer patients. See our latest analysis for Regeneron Pharmaceuticals. This regulatory progress adds to a busy stretch for Regeneron, which recently presented at the ESMO Congress and has continued ramping up share repurchases according to major...

Description: Biotech company Regeneron (NASDAQ:REGN) will be announcing earnings results this Tuesday before market open. Here’s what you need to know.

Description: ​Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy Right Now. On October 17, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced that the European Medicines Agency adopted a positive opinion for its Libtayo, which treats adults with cutaneous squamous cell carcinoma. Earlier this month, Libtayo was approved by the FDA to […]

Description: Sanofi stock jumped early Friday on better-than-expected third-quarter sales and earnings, and a strong showing from Dupixent.

Description: Investors next week will tune into big-tech earnings and the first Federal Reserve meeting since the U.S. government shutdown began. Later in the week, President Trump is due to meet with Chinese leader Xi Jinping as trade tensions between the two economic giants simmer.

Description: Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” third-quarter 2025 investor letter. The letter can be downloaded here. The fund returned -0.33% in the third quarter, compared to the S&P 500’s 8.12 % return and the Russell 1000 Value’s 5.33% return. The firm is not happy with the flat performance of the portfolio, […]

Description: Regeneron's Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition.

Description: Evaluate the expected performance of Regeneron (REGN) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Description: Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Biotech stocks Disc Medicine and Revolution Medicines jumped Friday after the duo received some of the first CNPVs.

Description: Regeneron Pharmaceuticals recently received U.S. FDA approval and a positive opinion from the European Medicines Agency's advisory committee for Libtayo (cemiplimab) as an adjuvant treatment for adult patients with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation. This regulatory progress not only reflects favorable Phase 3 clinical trial results, but also points to potential expansion of Regeneron's oncology portfolio and commercial...

Description: Positive opinion based on results of Phase 3 C-POST trial that show Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence interval: 0.20-0.51; p<0.0001), the primary endpoint of the trialTARRYTOWN, N.Y., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive